diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6183diaendo-6183Research ArticleСтатьиArticlesФизиологическая роль инкретинов: перспективы лечения больных сахарным диабетом 2 типаFiziologicheskaya rol' inkretinov:perspektivy lecheniya bol'nykhsakharnym diabetom 2 tipaГалстянГагик РадиковичGalstyanGagik Radikovich-ГУ Эндокринологический научный центр РАМН, МоскваEndocrinology Research Centre, Moscow20061512200694№4 (2006)1418Copyright © Галстян Г.Р., 20062006Галстян Г.Р.Galstyan G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6183

ГПП-1 и ГИП являются инкреторными гормонами, обладающими широким спектром действий в отношении регуляции углеводного обмена. Секреция ГПП-1 и ГИП аквтивируется в ответ на прием пищи, что способствует усилению секреции инсулина. ГПП-1 играет важную роль в снижении секреции глюкагона. Наличие зависимости действия инкретина на секреторный ответ бета- и альфа-клеток и уровня гликемии определяет низкий риск развития гипогликемических состояний и сохранение контринсулярной функции организма. Данные клинических исследований позволяют рассматривать аналоги ГПП-1 и ингибиторы ДПП-4 как новый класс лекарственных средств, которые можно применять как в виде монотерапии, так и в комбинации с другими сахароснижающими препаратами.

инкретинылечениесахарный диабетReferencesUnger RH, Eisentraut AM. Enteroinsular axis. Arch intern Med, 1969, 124, 261-266.Unger RH, Eisentraut AM. Enteroinsular axis. Arch intern Med, 1969, 124, 261-266.Gautier JF, Felita S., Sobngwi E. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metabolism 2005, 31, 233-242.Gautier JF, Felita S., Sobngwi E. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metabolism 2005, 31, 233-242.Drucker DJ. Minireview: the glucagons-like peptides. Endocrinology, 2001, 142, 521-527.Drucker DJ. Minireview: the glucagons-like peptides. Endocrinology, 2001, 142, 521-527.Orskov C., Wettergen A., Holst J. Secretion of incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gasroenterol, 1996, 31, 665-70.Orskov C., Wettergen A., Holst J. Secretion of incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gasroenterol, 1996, 31, 665-70.Holst J. Therapy of Type 2 diabetes mellitus based on actions of glucagons-like peptide-1. Diabetes Metab Res Rev, 2002, 18, 430-441.Holst J. Therapy of Type 2 diabetes mellitus based on actions of glucagons-like peptide-1. Diabetes Metab Res Rev, 2002, 18, 430-441.Fehmann H., Goke B., Goke R. Cell and molecular biology of the incretin hormones. Endocrine Rev, 1995, 16, 390-410.Fehmann H., Goke B., Goke R. Cell and molecular biology of the incretin hormones. Endocrine Rev, 1995, 16, 390-410.Nauk M., Heimesaat M., Behle K et al. Effects of GLP-1 on counter regulatory hormone responses. J Clin Endocrinol Metab, 2002, 87, 1239-46.Nauk M., Heimesaat M., Behle K et al. Effects of GLP-1 on counter regulatory hormone responses. J Clin Endocrinol Metab, 2002, 87, 1239-46.Nauck M. et al. Inhibition of gastric emptuing by physiological and pharmacological doses of exogenous GLP-1 outweights insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol, 1997, 273, E981-E988.Nauck M. et al. Inhibition of gastric emptuing by physiological and pharmacological doses of exogenous GLP-1 outweights insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol, 1997, 273, E981-E988.Flint A., Raben A. et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intakes in humans. J Clin Invest, 1998, 101, 515-520.Flint A., Raben A. et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intakes in humans. J Clin Invest, 1998, 101, 515-520.Naslund E. et al. Energy intake and appetide are suppressed by glucagons-like peptide in obese men. Int J Obes Relat Metab Disord, 1999, 23, 304-311.Naslund E. et al. Energy intake and appetide are suppressed by glucagons-like peptide in obese men. Int J Obes Relat Metab Disord, 1999, 23, 304-311.Gutzwiller J., Drewe J. et al. GLP-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol, 1999, 276, 1541-1544.Gutzwiller J., Drewe J. et al. GLP-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol, 1999, 276, 1541-1544.Drucker D.J. Glucagon-like peptide-1 and the islet _-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology, 2003, 144, 5145-8.Drucker D.J. Glucagon-like peptide-1 and the islet _-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology, 2003, 144, 5145-8.Farilla L., Bulotta A. et al. Glucagon-like peptide inhibits cell apoptosis and improves glucose responseveness of freshly isolated human islets. Endocrinology, 2003, 141, 5149-58.Farilla L., Bulotta A. et al. Glucagon-like peptide inhibits cell apoptosis and improves glucose responseveness of freshly isolated human islets. Endocrinology, 2003, 141, 5149-58.Toft-Nielsen M. et al. Determinants of the impaired secretion of glucagons-like peptide 1 in Type 2 diabetic patients. Diabetes, 2001, 86, 3717-3723.Toft-Nielsen M. et al. Determinants of the impaired secretion of glucagons-like peptide 1 in Type 2 diabetic patients. Diabetes, 2001, 86, 3717-3723.Nauk M., Heisematt M. Orskov C et al. Preserved incretin activity of GLP- 1 but not synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest, 1993, 30, 301-307.Nauk M., Heisematt M. Orskov C et al. Preserved incretin activity of GLP- 1 but not synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest, 1993, 30, 301-307.Willms B., Werner J. et al. Gastric emptying, glucose responses, and insulin secretion after a liquid meal. J Clin Endocrinol Metab, 1996, 81, 327-332.Willms B., Werner J. et al. Gastric emptying, glucose responses, and insulin secretion after a liquid meal. J Clin Endocrinol Metab, 1996, 81, 327-332.Pospisilik J. et al. DDPIv treatment stimulates beta-cell survival and islet neogenesis in sterptozotocin-induced diabetic rats. Diabetes (2003) 52: 741-740.Pospisilik J. et al. DDPIv treatment stimulates beta-cell survival and islet neogenesis in sterptozotocin-induced diabetic rats. Diabetes (2003) 52: 741-740.Li Y et al. GLP-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. (2003) 278: 471-478.Li Y et al. GLP-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. (2003) 278: 471-478.Bose A., et al. GLP-1 protcts ischemic and reperfused myocardium via PI3 kinase and p42|p44 MAPK signaling pathways. Diabetes (2004) 53 (Suppl.2): A1, 2.Bose A., et al. GLP-1 protcts ischemic and reperfused myocardium via PI3 kinase and p42|p44 MAPK signaling pathways. Diabetes (2004) 53 (Suppl.2): A1, 2.

The authors declare that there are no conflicts of interest present.